Galapagos (GLPG) to Release Quarterly Earnings on Friday

Galapagos (NASDAQ:GLPG) will likely be posting its quarterly earnings results after the market closes on Friday, February 28th. Analysts expect Galapagos to post earnings of ($0.24) per share and revenue of $73.08 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Galapagos Stock Down 0.4 %

Galapagos stock opened at $26.40 on Thursday. The business’s 50-day moving average price is $25.39 and its 200 day moving average price is $27.09. Galapagos has a 52 week low of $22.36 and a 52 week high of $37.22.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th. Barclays reissued an “underweight” rating on shares of Galapagos in a research note on Thursday, January 23rd. Morgan Stanley downgraded Galapagos from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $31.00 to $22.00 in a report on Friday, February 14th. Royal Bank of Canada decreased their price target on Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a report on Friday, November 1st. Finally, TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Five research analysts have rated the stock with a sell rating and five have given a hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $26.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.